Published :
Tables : 62
Figures : 50
Category : Healthcare
No. of Pages : 220
Report Code : HC-U3316
Microbubbles or Ultrasound Contrast Agents Market is poised to value over USD 2 billion by 2027 end with a CAGR of over 24.8% during the forecast period 2020 to 2027. Microbubbles are capable of reflecting ultrasound waves and they are intravenously administered and are circulated in the blood like red blood cells. These gas bubbles are applied with ultrasound pulses with a certain frequency and the bubbles change their dimensions, thereby creating a strong echo from the perfused tissue area. Therefore, using microbubble contrast reagents for ultrasound diagnosis helps in improving the backscattering or ultrasound reflection of the waves which leads to the production of an echocardiogram with contrast enhancements. The microbubbles have a fundamental disadvantage. They do not last longer in circulation and this shall affect the outcome of the echocardiogram of a complex tumor. Market Segmentation: By Disease Area • Cardiovascular Diseases • Renal Diseases • Others By Application • Drug Delivery • Molecular Imaging • Stem Cell Delivery • Gene Therapy By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into disease area, application and region. The disease area segment is fragmented into renal diseases, cardiovascular diseases and others. The cardiovascular disease segment is anticipated to account for the largest microbubbles or ultrasound contrast agents market share and this can be credited to a rise in the number of patients diagnosed with cardiovascular diseases, increased adoption of microbubbles in echocardiogram procedures for obtaining an optimum echocardiogram to effectively analyse the issue. The application segment is bifurcated into drug delivery, molecular imaging, stem cell delivery and gene therapy. The molecular imaging segment is anticipated to lead the market, and this can be attributed to an increased acceptance of microbubbles in different diagnostic procedures that are based on ultrasound technology. Furthermore, a rising necessity for monitoring the biomarker status in imaging inflammation, vascular endothelium and visualizing the vasculature of a tumor has boosted the proliferation of the market. Regional Analysis: The North America region is predicted to dominate the market, and this is due to the increased cancer patient population along with a rise in the adoption of ultrasound procedures integrated with microbubbles. Furthermore, a strong presence of key market players has bolstered the market growth in the region. However, the Asia Pacific region is predicted to grow at substantial rate and this growth will be mainly driven by countries like India, Japan, South Korea with a rise in the awareness programs undertaken by the government bodies for improving public health and advancements in the healthcare infrastructure developed in the region. Competitive Landscape: The prominent players of the market include GE Healthcare, Bristol-Myers Squibb, Daiichi Sankyo Company Limited, Lantheus Holdings Inc., Bracco, nanoPET Pharma GmbH. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global microbubbles or ultrasound contrast agents market by disease area, by application and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Microbubbles are capable of reflecting ultrasound waves and they are intravenously administered and are circulated in the blood like red blood cells. These gas bubbles are applied with ultrasound pulses with a certain frequency and the bubbles change their dimensions, thereby creating a strong echo from the perfused tissue area. Therefore, using microbubble contrast reagents for ultrasound diagnosis helps in improving the backscattering or ultrasound reflection of the waves which leads to the production of an echocardiogram with contrast enhancements. The microbubbles have a fundamental disadvantage. They do not last longer in circulation and this shall affect the outcome of the echocardiogram of a complex tumor.
Market Segmentation:
By Disease Area • Cardiovascular Diseases • Renal Diseases • Others By Application • Drug Delivery • Molecular Imaging • Stem Cell Delivery • Gene Therapy By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into disease area, application and region. The disease area segment is fragmented into renal diseases, cardiovascular diseases and others. The cardiovascular disease segment is anticipated to account for the largest microbubbles or ultrasound contrast agents market share and this can be credited to a rise in the number of patients diagnosed with cardiovascular diseases, increased adoption of microbubbles in echocardiogram procedures for obtaining an optimum echocardiogram to effectively analyse the issue. The application segment is bifurcated into drug delivery, molecular imaging, stem cell delivery and gene therapy. The molecular imaging segment is anticipated to lead the market, and this can be attributed to an increased acceptance of microbubbles in different diagnostic procedures that are based on ultrasound technology. Furthermore, a rising necessity for monitoring the biomarker status in imaging inflammation, vascular endothelium and visualizing the vasculature of a tumor has boosted the proliferation of the market.
Regional Analysis:
The North America region is predicted to dominate the market, and this is due to the increased cancer patient population along with a rise in the adoption of ultrasound procedures integrated with microbubbles. Furthermore, a strong presence of key market players has bolstered the market growth in the region. However, the Asia Pacific region is predicted to grow at substantial rate and this growth will be mainly driven by countries like India, Japan, South Korea with a rise in the awareness programs undertaken by the government bodies for improving public health and advancements in the healthcare infrastructure developed in the region.
Competitive Landscape:
The prominent players of the market include GE Healthcare, Bristol-Myers Squibb, Daiichi Sankyo Company Limited, Lantheus Holdings Inc., Bracco, nanoPET Pharma GmbH.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global microbubbles or ultrasound contrast agents market by disease area, by application and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Microbubbles or Ultrasound Contrast Agents Market, By Disease Area Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Cardiovascular Diseases 7.2 Renal Diseases 7.3 Others 8. Microbubbles or Ultrasound Contrast Agents Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Drug Delivery 8.2 Molecular Imaging 8.3 Stem Cell Delivery 8.4 Gene Therapy 9. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 9.2.1. U.S. 9.2.2. Canada 9.2.3. Mexico 9.2.3 Rest of North America 9.3 Market Size (USD Mn) Forecast for North America 2020-2027 10. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 10.3.1. Brazil 10.3.2. Uruguay 10.3.3 Argentina 10.3.4. Rest of Latin America 10.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 11. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5 Switzerland 11.2.6. Spain 11.2.7. Russia 11.2.8. Poland 11.2.9. Rest of Western Europe 11.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 12. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1 Introduction 12.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 12.2.1 Japan 11.2.2 China 12.2.3 Singapore 12.2.4 Korea 12.2.5 India 12.2.6 Australia and New Zealand 12.2.7 ASEAN 12.2.8 Rest of Asia Pacific 12.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 UAE 13.2.2 South Africa 13.2.3 Egypt 13.2.4 Saudi Arabia 13.2.5 Rest of MEA 13.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 14.1 GE Healthcare 14.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2 Bristol-Myers Squibb 14.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3 Daiichi Sankyo Company Limited 14.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4 Lantheus Holdings Inc. 14.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Bracco 14.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 nanoPET Pharma GmbH 14.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 15. Impact of COVID-19 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. Competitive Intelligence and Competitive Matrix 16.1 Competitive Intelligence 16.2 Competitive Matrix 17. Major Deals and Strategic Alliances Analysis 17.1 Joint ventures 17.2 Mergers and acquisitions 17.3 Licensing and partnerships 17.4 Technology Collaborations 17.5 Strategic Divestments 17.6 Market Entry Strategies 18. Relevant Case Studies and Latest News Updates 19. Research Sources and List of Primary Contacts of this Study 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics